<DOC>
	<DOCNO>NCT02277132</DOCNO>
	<brief_summary>Rationale : Severe , early-onset fetal growth restriction ( FGR ) due placental insufficiency associate high risk perinatal morbidity long-lasting sequela mortality . Placental insufficiency result abnormal formation function placenta ( placentation ) inadequate remodelling maternal spiral ( uteroplacental ) artery . There currently therapy available demonstrated effectiveness . Evidence suggest Sildenafil citrate improve uteroplacental blood flow , growth , meaningful outcome . Objective : To evaluate effectiveness sildenafil ( versus placebo ) achieve healthy perinatal survival . Study design : Multicenter nationwide randomize placebo-controlled clinical trial . Study population : Women singleton pregnancy 20 30 week severe fetal growth restriction likely placental origin , estimate significant likelihood perinatal death . Intervention : Sildenafil 25mg placebo tablet orally three time daily . Main study parameters/endpoints : Perinatal healthy survival , i.e . survival without severe neonatal morbidity term age . Nature extent burden risk associate participation , benefit group relatedness : Taking tablet three time daily . No additional ultrasound , standard clinical protocol , one extra blood sample inclusion . No risk anticipate , unexpected medication-associated risk ca n't exclude beforehand .</brief_summary>
	<brief_title>The Dutch STRIDER ( Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction )</brief_title>
	<detailed_description />
	<mesh_term>Fetal Growth Retardation</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Inclusion criterion ( ( I OR II ) AND III ) : At 20+027+6 week : ultrasound measurement fetal abdominal circumference ( AC ) &lt; 3rd percentile gestational age ultrasound estimate fetal weight ( EFW ) &lt; 5th percentile OR At 28+029+6 week : ultrasound estimate fetal weight ( EFW ) &lt; 700 gram use Hadlock C formula AND Likely placental origin define ( AND/OR b AND/OR c AND/OR ) The presence uterine artery notch Abnormal flow velocity pattern umbilical artery middle cerebral artery Maternal hypertensive disorder Low PlGF pointofcare assessment Plan terminate pregnancy maternal fetal indication within day Known multiple pregnancy Identified congenital anomaly congenital infection Maternal age eligibility &lt; 18 year Cocaine use Current use sildenafil Current use cyp3A5 inhibitor : amiodaron , azitromycine , ciclosporine , claritromycine , diltiazem , erytromycine , fluconazol , itraconazol , ketoconazol , verapamil , voriconazol . Recent myocardial infarction stroke</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Fetal growth restriction</keyword>
	<keyword>Sildenafil</keyword>
</DOC>